Menopur (Menotrophin)

Menotropin provides both FSH and LH activity. FSH binds to receptors on granulosa cells, promoting follicle growth and estradiol synthesis, while LH acts on theca cells and later on mature granulosa cells to support androgen production and final oocyte maturation. The combined effect mimics the natural pituitary surge, leading to development of multiple follicles.

The prescribed dose of Menopur is individualized by the treating physician based on the patient’s ovarian reserve, response to prior stimulation, and the specific assisted reproduction protocol. The prescriber determines the number of international units (IU) per injection and the duration of treatment, adjusting as needed during monitoring.

Menopur is intended for use before conception to induce ovulation; it is not administered during an established pregnancy. Its safety in pregnancy has not been established, and it is generally contraindicated. Limited data are available for breastfeeding, and the product should be avoided unless the benefits outweigh potential risks as assessed by a healthcare professional.

To request Menopur, visit the product page on gnhindia.com, enter the desired quantity, and submit the inquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifying trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain handling if required), and necessary import documentation.

Menopur contains both FSH and LH activity in a single preparation, whereas some alternatives provide only FSH (e.g., recombinant FSH) and require separate LH supplementation. The combined formulation can simplify dosing and may be advantageous in patients who benefit from LH activity, but individual response and cost considerations determine the preferred product for each treatment cycle.

Menopur must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Keep the vials in the original packaging until use, and discard any solution that appears discolored or contains particles. Follow local pharmacy or clinic protocols for cold‑chain management during transport.

Menopur is supplied as a sterile injectable solution for intramuscular or subcutaneous injection. The medication is reconstituted with the appropriate diluent according to the package insert, and the prescribed dose is drawn into a sterile syringe. Injections are typically given once daily, but the exact schedule is determined by the treating physician.

The most serious risk is ovarian hyperstimulation syndrome (OHSS), which can range from mild abdominal discomfort to severe fluid accumulation, electrolyte imbalance, and thromboembolic complications requiring hospitalization. Rarely, allergic reactions including anaphylaxis may occur. Patients should be monitored closely for signs of OHSS and any severe adverse events.

Menopur is contraindicated in women with known hypersensitivity to menotropin or any excipients, those with ovarian cysts, uncontrolled thyroid disease, active malignancy, or established pregnancy. It should also be avoided in patients with severe ovarian hyperstimulation syndrome risk factors unless the benefits clearly outweigh the risks, as assessed by a qualified clinician.